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Aims: The GLP-1 receptor agonist liraglutide improves impaired pancreatic β-cell function, thereby exerting
glucose-lowering effects. However, the association of remaining β-cell function with long-term therapeutic
efﬁcacy of liraglutide remains largely unknown.
Methods: Patients with type 2 diabetes who started liraglutide as monotherapy or sulfonylurea-combination
therapy were retrospectively analyzed to identify possible associations of indices related to β-cell function
including increments of C-peptide immunoreactivity in glucagon stimulation test (GST-ΔCPR) with
achievement of HbA1c b7.0% at 54 weeks after liraglutide initiation.
Results: Among 165 subjects continuing liraglutide for 54 weeks, 66 received additional oral anti-diabetic
drugs (OADs) during the period. Of those continuing liraglutidewithout receiving additional OADs, 41 subjects
achieved HbA1c b7.0% at 54 weeks, while 49 subjects did not. Subjects achieving HbA1c b7.0% showed higher
values of GST-ΔCPR. Receiver-operating analysis revealed 2.34 ng/mL as the cut-off value for HbA1c b7.0%
achievement in these subjects. Subjects with GST-ΔCPR N2.34 ng/mL showed continuous and substantial
HbA1c reduction throughout the 54 weeks. In Kaplan–Meier analysis, subjects with GST-ΔCPR N2.34 ng/mL
showed longer therapeutic durability of initial liraglutide therapy with no additional OADs or insulin.
Conclusions: Despite numerous limitations, these results indicate that long-term efﬁcacy of liraglutide is
associated with remaining β-cell function at initiation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Type 2 diabetes is a heterogeneous disease characterized by β-cell
dysfunction and insulin resistance (DeFronzo, 1988; Stumvoll,
Goldstein, & van Haeften, 2005; Yabe, Seino, Fukushima, & Seino,
2015). Due to progressive decline in β-cell function, anti-diabetic
treatment regimens must be adjusted over time based on estimates of
the remaining insulin secretory capacity. Conventional anti-diabetic
drugs that compensate for reduced insulin secretion include insulin
and sulfonylurea (SU), both of which have been shown to maintain
optimal glycemic control and to prevent progression of diabetes-re-
lated complications (Anonymous, 1999; Holman, Paul, Bethel,
Matthews, & Neil, 2008). However, insulin and SU are associated
with varying degrees of hypoglycemia and weight gain (Anonymous,
1998; Best et al., 2012). Glucagon-like peptide-1 (GLP-1) receptor
agonists are emerging anti-diabetic drugs that enhance insulin
secretion glucose-dependently as well as suppress glucagon secretion
and slow gastric emptying, thereby improving glycemic control and
reducing bodyweight in patients with type 2 diabetes (Meier, 2012;
Yabe, Kuwata, Usui, Kurose, & Seino, 2015; Yabe & Seino, 2014).
Clinical trials of GLP-1 receptor agonists comparing their efﬁcacy and
safety with those of insulin or SU show that GLP-1 receptor agonists
are capable of achieving appropriate glycemic control with reduced
risk of hypoglycemia and bodyweight gain (Meier, 2012; Yabe,
Kuwata, Usui, Kurose, & Seino, 2015; Yabe & Seino, 2014). However,
the long-term therapeutic effects of GLP-1 receptor agonists in clinical
practice need to be evaluated.
Liraglutide is a once daily injectable GLP-1 receptor agonist, with a
Lys34Arg substitution and the addition of a C16-fatty acid at Lys26 in
human GLP-1 (Best et al., 2012; Faber & Binder, 1977; Fujita et al.,
2015; Funakoshi et al., 2011; Gjessing, Matzen, Froland, & Faber, 1987;
Greenbaum et al., 2008; Hendriksen, Faber, Drejer, & Binder, 1977;
Iwao, Sakai, & Sata, 2013; Iwata et al., 2014; Kajinuma et al., 1979;
Kaku, Rasmussen, Clauson, & Seino, 2010; Kaku, Rasmussen, Nishida,
& Seino, 2011; Kondo et al., 2013; Kozawa et al., 2012; Lapolla et al.,
2015; Matsuda, Kamata, Iwamoto, Sakamoto, & Kuzuya, 1985; Meier,
2012; Ponzani, 2013; Retnakaran, Kramer, Choi, Swaminathan, &
Zinman, 2014; Saisho et al., 2011; Seino, Rasmussen, Clauson, & Kaku,
2012; Seino, Rasmussen, Nishida, & Kaku, 2010; Seino et al., 2010;
Shao, Yuan, Feng, Zhang, & Guo, 2014; Toyoda, Yokoyama, Abe,
Nakamura, & Suzuki, 2014; Usui et al., 2013; Vilsboll et al., 2008; Yabe,
Kuwata, Usui, Kurose, & Seino, 2015; Yabe & Seino, 2011, 2014;
Yamada et al., 2006). This endows resistance to degradation of GLP-1
mediated by dipeptidyl peptidase-4 and its stabilization in human
circulation as an albumin bound form. Liraglutide has been shown to
exert its glucose-lowering effects partly by ameliorating impaired
glucose-dependent insulin secretion from β-cells, one of the major
defects in type 2 diabetes (Seino et al., 2012; Vilsboll et al., 2008). It
has been reported that early liraglutide initiation in type 2 diabetes as
well as in experimental animals exerts superior improvement on
β-cell function and better glycemic control (Retnakaran et al., 2014;
Shao et al., 2014), suggesting that remaining β-cell function might
predict the glucose-lowering effects of liraglutide. While several
clinical studies have demonstrated that liraglutide results in greater
HbA1c reduction in early stage diabetes (Iwao et al., 2013; Lapolla et
al., 2015; Ponzani, 2013; Toyoda et al., 2014), clinical investigations of
direct association of β-cell function with glucose-lowering effects of
liraglutide, especially at longer time points, are few. To assess β-cell
function in patients with type 2 diabetes in clinical settings, several
indices using serum C-peptide immunoreactivity (CPR) are used:
glucagon-stimulated increments of CPR (Faber & Binder, 1977; Fujita
et al., 2015; Gjessing et al., 1987; Hendriksen et al., 1977), fasting and
postprandial C-peptide index (CPI) (Funakoshi et al., 2011; Saisho
et al., 2011), and secretory units of islets in transplantation (SUIT)
(Funakoshi et al., 2011; Iwata et al., 2014; Yamada et al., 2006). While
glucagon-stimulated increments of CPR are ideal for assessment ofβ-cell function, CPI and SUIT were used because they are more readily
evaluated in actual clinical settings. These CPR-related indices for
β-cell function have been used to predict requirements for insulin
injections in patients with type 2 diabetes (Funakoshi et al., 2011;
Iwata et al., 2014; Saisho et al., 2011). We and others have reported
that these CPR-related indices can predict successful switch from
insulin to liraglutide (Kondo et al., 2013; Kozawa et al., 2012; Usui
et al., 2013), but the associations of these CPR-related indices with
long-term therapeutic efﬁcacy of liraglutide have not been
investigated.
In the current study, we evaluated the role of remaining β-cell
function in relation to long-term therapeutic efﬁcacy of liraglutide in
Japanese patients with type 2 diabetes.
2. Materials and methods
2.1. Participants
Two hundred seventy-two patients with type 2 diabetes who
started liraglutide therapy at Kansai Electric Power Hospital between
June 2010 and March 2012 were retrospectively analyzed in the
current study. None of the patients had type 1 diabetes, pancreatic
disease, liver disease, renal disease, malignancy or were taking
diabetogenic medication or were pregnant. Type 1 diabetes was
diagnosed by auto-antibodies such as anti-GADantibody and anti-IA-2
antibody according to the diagnostic criteria of type 1 diabetes by the
Japan Diabetes Society (Seino, Nanjo, et al., 2010). Patients with renal
failure and/or those taking dialysis were excluded, since serum CPR
levels are modiﬁed in these conditions. Insulin-dependent patients
were also excluded for lack of β-cell function. Insulin-dependencywas
deﬁned by combinations of fasting CPR ≤0.5 ng/mL, stimulated CPR
≤1.0 ng/mL, and urinary CPR ≤20 μg/day (Matsuda et al., 1985). The
duration of type 2 diabetes was deﬁned as years after diagnosis of the
disease according to the criteria of the Japan Diabetes Society. Physical
and laboratory data including HbA1c were acquired in all patients
before and every 6 weeks after starting liraglutide therapy. Inclusion
and exclusion of the study subjects are summarized in Fig. 1. Of the 272
patients, 22 were excluded from analysis because they were referred
to other clinics or stopped hospital visits for unknown reasons during
the 54 week period. The baseline clinical proﬁles and parameters of
the remaining 250 patients are shown in Table 1. Of them, 26 patients
discontinued liraglutide during the 54 weeks due to adverse events
(nausea n = 6, skin rash n = 1, others n = 19), and 59 patients
discontinued liraglutide due to hyperglycemia. Sixty-six patients
received additional OADs during the 54 weeks (8 patients, HbA1c at
54 weekswas not available), and the remaining 99 patients continued
liraglutide during the 54 weeks without adding any OAD (9 patients,
HbA1c at 54 weeks was not available). Severe hypoglycemia was
deﬁned as requiring assistance of another person to actively
administer carbohydrate, glucagon or other resuscitative actions.
Non-severe hypoglycemia was not evaluated in the current study,
since its deﬁnition varied among the physicians in charge.
2.2. Measurements
HbA1c was measured using high performance liquid chromatog-
raphy with cation-exchange resins that separate the stable form of
β-N1-mono-deoxyfructosyl Hb; the values are shown in National
Glycohemoglobin Standardization Program units as recommended by
the Japan Diabetes Society (Seino, Nanjo, et al., 2010). Glucagon
stimulation test (GST) was carried out after an overnight fast by
measuring serumCPR at fasting or 6 min after intravenous injection of
1 mg glucagon (CPR-0 min and CPR-6 min, respectively) (Kajinuma
et al., 1979). In patients who received insulin therapy before starting
liraglutide therapy, insulin injections were continued to avoid
hyperglycemia until the night before measuring fasting and/or
Fig. 1. Schematic diagram of the current retrospective analysis.
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were stoppeduntil the endof theglucagon stimulation test. Antidiabetic
drugswere also stopped for the glucagon test, butweremaintaineduntil
1 day before the test. The glucagon stimulation test was carried out
when fasting plasma glucose levels reached ≥80 mg/dL similarly to
previous studies (Greenbaum et al., 2008) because hypoglycemiamight
affect β-cell response to glucagon. Increments of CPR after glucagon
stimulation test (GST-ΔCPR), C-peptide index (CPI) and secretoryunit of
islet in transplantation (SUIT) were calculated as follows: GST-ΔCPR
(ng/mL), (CPR-6 min) − (CPR-0 min); CPI, (fasting CPR)/(fasting
plasma glucose) × 100; SUIT, 1500 × (fasting C-peptide)/((fasting
plasma glucose) − 63). Serum C-peptide was measured using lumi-
pulse presto C-peptide (Fujirebio Inc., Tokyo, Japan). Intra- and
inter-assay variations of measurement of serum CPR levels were
1.96%–2.97% and 1.06%–2.60%, respectively. Other laboratory measure-
ments including plasma glucose were measured by standard assays.2.3. Statistical analysis
Patient characteristics and results are reported as mean ±
standard error of themean unless otherwise stated. Statistical analysis
was carried out using IBM SPSS Statistics version 22 (SAS Institute Inc.,Cary, NC, USA). Repeated measures were analyzed by mixed effects
model. Clinical parameters between the two groups at single time-
points were compared by Mann–Whitney U-test. The receiver-
operating characteristic (ROC) curve was constructed for CPR-0 min,
CPR-6 min, GST-ΔCPR, CPI and SUIT. Sensitivity, speciﬁcity, cut-off
point, area under the ROC curve (AUC) and the likelihood ratio were
also calculated. The Kaplan–Meier method was used to analyze
durability of initial therapy, and the difference was examined using
log-rank test. p values b0.05 were considered statistically signiﬁcant.3. Results
Of 165 patients who continued liraglutide during the 54 weeks, 66
patients also received additional OADs during the test period (Fig. 1).
The remaining 99 patients continued liraglutide without receiving
additional OADs. Of these patients, 41 achievedHbA1c less than 7.0% at
54 weeks. Sixteen of these patients had GST data at baseline; 25 of
them did not take the GST. Forty-nine of the patients showed HbA1c
7.0% or more at 54 weeks. Twenty-ﬁve of these patients had GST data;
22 of them did not take the GST, and 2 of them were excluded from
analysis because their Ccr level was less than 30, whichmight possibly
affect GST values. Nine of the 99 patients had no HbA1c data at
Table 1
Baseline characteristics of patients with type 2 diabetes before liraglutide initiation.
All patients Patients receiving no additional
OAD during 0–54 weeks
Patients receiving additional
OAD during 0–54 weeks
N (% male) 250 (66.8%) 90 (66.7%) 58 (62.1%)
Age at 0 week (years) 63.0 ± 0.8 62.0 ± 1.2 62.7 ± 1.6
Estimated duration at 0 week (years) 13.6 ± 0.6 11.6 ± 0.9 12.6 ± 1.1
BMI at 0 week (kg/m2) 26.5 ± 0.3 27.0 ± 0.5 26.3 ± 0.7
Initiated as monotherapy or sulfonylurea combination (%) 60.0/40.0 57.8/42.2 72.4/27.6
Insulin use before liraglutide initiation (%) 80 74 81
OAD use before liraglutide initiation (%)
Sulfonylureas 28 30 29
Metformin 24 21 26
Glinides 13 13 12
α-glycosidase inhibitors 10 7 12
Thiazolidinedione 6 1 7
DPP-4 inhibitors 8 6 9
CPI at 0 week 1.28 ± 0.06 1.41 ± 0.11 1.25 ± 0.13
SUIT at 0 week 46.4 ± 3.4 48.2 ± 4.4 41.6 ± 4.3
GST-CPR0 min at 0 week 1.64 ± 0.09 1.87 ± 0.18 1.67 ± 0.20
GST-CPR6 min at 0 week 3.27 ± 0.18 4.01 ± 0.36 3.18 ± 0.35
GST-ΔCPR at 0 week 1.63 ± 0.10 2.14 ± 0.20 1.52 ± 0.19
Liraglutide dosage at 54 weeks (mg) – 0.79 ± 0.02 0.85 ± 0.01
HbA1c at 0 week (%) 8.1 ± 0.1 7.8 ± 0.1 8.2 ± 0.2⁎
HbA1c at 54 weeks (%)a 7.4 ± 0.1 7.1 ± 0.1 7.9 ± 0.1⁎
Patients with HbA1c b7% at 0 week (%) 16.0 22.2 12.1
Patients with HbA1c b7% at 54 weeks (%)a 32.8 45.6 13.8
Each value represents the mean ± SEM. BMI, body mass index. CPI, 100 × [fasting serum C-peptide (ng/mL)]/[fasting plasma glucose (mg/dL)]. GST-ΔCPR, increment of serum
C-peptide levels before and 6 min after iv administration of 1 mg glucagon (GST-CPR0 min and GST-CPR6 min, respectively). BMI, body mass index; CPI, C-peptide index; DPP-4,
dipeptidyl peptidase-4; GST, glucagon stimulation test; OAD, oral anti-diabetic drugs; SUIT, secretory unit of islet in transplantation. Liraglutide dosages at 54 weeks for patients
receiving no additional OAD during 0–54 weeks and those receiving additional OAD during 0–54 weeks are shown. Liraglutide up to 0.9 mg q.d. is approved in Japan.
a Values are calculated for patients who have HbA1c values at 54 weeks.
⁎ Denotes p b 0.05 in Mann–Whitney U-test (versus continued).
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Compared with patients receiving additional OADs during 0–
54 weeks, patients receiving no additional OAD showed signiﬁcantly
lower HbA1c at 0 week (7.8% ± 0.1% vs 8.2% ± 0.2%) and 54 weeks
(7.1% ± 0.1% vs 7.9% ± 0.1%). The indices related to β-cell function
showed a signiﬁcantly higher value of GST-ΔCPR (ng/mL) (2.14 ±
0.20 vs 1.52 ± 0.19, p b 0.05), indicating that remaining β-cell
function plays a role in the glucose-lowering effects of liraglutide.
To address possible correlation of remaining β-cell function with
the glucose-lowering effects of liraglutide, indices related to β-cell
function at baseline between patients with HbA1c b7.0% and those
with HbA1c ≥7.0% at 54 weeks were compared. Patients having
HbA1c b7.0% at 54 weeks showed signiﬁcantly higher values of
GST-CPR0 min, GST-CPR6 min, and GST-ΔCPR than those with HbA1c
≥7.0% at 54 weeks [GST-CPR0 min (ng/mL), 2.19 ± 0.25 vs 1.67 ±
0.24, p = 0.049; GST-CPR6 min (ng/mL), 5.03 ± 0.52 vs 3.36 ± 0.44,
p = 0.006; GST-ΔCPR (ng/mL) 2.84 ± 0.33 vs 1.70 ± 0.22, p =
0.003] (Fig. 2A). They also had higher values of CPI and SUIT [CPI,
1.58 ± 0.19 vs 1.13 ± 0.12, p = 0.065; SUIT, 45.9 ± 6.4 vs 42.1 ±
6.3, p = 0.331], although the difference did not reach statistical
signiﬁcance. The mean values of GST-ΔCPR, CPI and SUIT in our
patients were somewhat lower than those in healthy controls:
GST-ΔCPR, 3.29 ± 1.21 ng/mL (Fujita et al., 2015) and 3.30 ±
1.14 ng/mL (Matsuda et al., 1985); CPI, 1.66 ± 0.55 (Fujita et al.,
2015); and SUIT 100 ± 11.7 (Yamada et al., 2006).
To determine the cut-off values for achieving HbA1c b7.0% at
54 weeks, ROC analyses were carried out for CPR-0 min, CPR-6 min,
GST-ΔCPR, CPI and SUIT; GST-ΔCPR at baseline showed the largest
AUC [0.780, 95% conﬁdence interval 0.627–0.933] with the cut-off
point estimated to be 2.34 ng/mL with 69% sensitivity and 84%
speciﬁcity (Fig. 2B). AUCs and the cut-off points of other parameters
such as GST-CPR0 min, GST-CPR6 min, CPI and SUIT are shown
in Fig. 2B.
Using the estimated cut-off value of GST-ΔCPR at baseline, HbA1c
and bodyweight over the 54 week period were compared betweenpatients with GST-ΔCPR ≤2.34 ng/mL and those with GST-ΔCPR
N2.34 ng/mL. In both groups, liraglutide initiation signiﬁcantly
reduced HbA1c throughout the 54 week period, but more so in patients
with GST-ΔCPR N2.34 ng/mL. HbA1c changes between 0 and 54 weeks
were signiﬁcantly different in the two groups (GST-ΔCPR N2.34 ng/mL,
−1.77% ± 0.57% and GST-ΔCPR ≤2.34 ng/mL, −0.66% ± 0.34%,
p b 0.01) (Fig. 3A). Patients with GST-ΔCPR N2.34 ng/mL showed
signiﬁcantly higher bodyweight at baseline than those with GST-ΔCPR
≤2.34 ng/mL, but bodyweight was reduced by liraglutide initiation in
both groups and bodyweight changes were not signiﬁcantly
different (GST-ΔCPR N2.34 ng/mL, −4.30 ± 0.93 kg and GST-ΔCPR
≤2.34 ng/mL, −4.45 ± 0.82 kg; p = 0.507) (Fig. 3B). Durability of
liraglutide was assessed by Kaplan–Meier analysis of patient GST-ΔCPR
at baseline. Patients who discontinued liraglutide due to AEs other than
hyperglycemia and those whowere referred to other clinics or stopped
hospital visits for unknown reasons were excluded. Among the
remaining patients (GST-ΔCPR ≤2.34 ng/mL, n = 93; and GST-ΔCPR
N2.34 ng/mL, n = 22), time before receiving another OAD or switch to
insulin tomaintain glycemic controlwas signiﬁcantly different between
the two groups (log-rank test, p = 0.0013) (Fig. 4), indicating that
liraglutide exerts longer-term therapeutic durability in patients with
greater remaining β-cell function.
4. Discussion
In the current retrospective study, we ﬁnd that the GLP-1 receptor
agonist liraglutide has substantial and continuous HbA1c-lowering
effects in patientswith sufﬁcient remaining pancreatic β-cell function.
ROC analysis reveals cut-off values of GST-ΔCPR that predict HbA1c
b7.0% achievement and associate with longer duration before patients
are switched to insulin injection or additional OAD.
Consistent with previously reported clinical trials conducted in
Japan (Kaku et al., 2010; Kaku et al., 2011; Seino, Rasmussen, Nishida,
& Kaku, 2010; Seino, Rasmussen, Nishida, & Kaku, 2011), we found
that liraglutide, initiated as monotherapy or SU-combination therapy,
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Fig. 2. (A) Comparison of β-cell function related indices in patients with HbA1c less than 7% at 0 week (blue, n = 7; sulfonylureas-combination n = 3 and monotherapy n = 4)
and 54 weeks (hatched blue, n = 16; sulfonylureas-combination n = 4 and monotherapy n = 12) and those with HbA1c 7% or above at 0 week (red, n = 34;
sulfonylureas-combination n = 11, and monotherapy n = 23) and 54 weeks (hatched red, n = 25; sulfonylureas-combination n = 10, and monotherapy n = 15). GST-ΔCPR,
increment of serum C-peptide levels before and 6 min after iv administration of 1 mg glucagon (GST-CPR0 min and GST-CPR6 min, respectively); CPI, 100 × [fasting serum
C-peptide (ng/mL)]/[fasting plasma glucose (mg/dL)]; SUIT, 1500 × [fasting C-peptide (ng/ml)]/([fasting plasma glucose (mg/dl)] − 63). Each value represents mean ± SEM. * and
** denote p b 0.05 and p b 0.01, respectively (Mann–Whitney U-test, versus continued). (B) Receiver-operating characteristic (ROC) curves of β-cell function-related indices
(CPR-0 min, CPR-6 min, GST-ΔCPR, CPI and SUIT) to predict for HbA1c less than 7% achievement at 54 weeks without adding additional anti-diabetic drugs. CPI, C-peptide index;
CPR, C-peptide immunoreactivity; GST, glucagon stimulation test; SUIT, secretory unit of islet in transplantation.
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cases of adverse events in clinical settings. However, due to
inadequate glycemic control, 23.6% of patients were discontinued on
liraglutide and received insulin injection (Fig. 1) and 26.4% received
additional OADs within 54 weeks after liraglutide initiation. Even
among patients who continued liraglutide for 54 weeks without
receiving additional OADs, only half achieved HbA1c b 7.0% (Fig. S1).
We found that patients with shorter duration of type 2 diabetes and
those not receiving insulin before liraglutide showed greater
reduction of HbA1c independent of baseline BMI (Fig. S3). Others
have reported that liraglutide exerts greater HbA1c-lowering effects
with shorter duration of disease (Toyoda et al., 2014). Previously, we
reported that increment of CPR in glucagon stimulation testpredicts inadequate glycemic control within 12 weeks after insulin-
to-liraglutide switch (Usui et al., 2013); others have reported that
remaining β-cell function predicted short-term efﬁcacy of liraglutide
(Meier, Vilsbøll, Donsmark, Hartvig, & M.A. N., 2011). Our current
study clearly indicates that liraglutide has sustained HbA1c-lowering
effects in patients with greater β-cell function in the values of
GST-ΔCPR (Fig. 2). ROC analysis reveals GST-ΔCPR 2.34 ng/mL as
cut-off value for achieving HbA1c b7.0% at 54 weeks. This predicted
both substantial HbA1c-lowering effects and longer time before
switch to insulin injection or additional OAD. (Fig. 4) Our cut-off
values for achieving HbA1c b7.0% (GST-ΔCPR 2.34 ng/mL and CPI
1.86) are considerably higher than those reported to avoid hypergly-
cemia within 12 weeks after insulin-to-liraglutide switch (Kozawa et
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Fig. 3. Changes during 54 week observational periods in HbA1c (A) and bodyweight (B) in patients with GST-ΔCPR N2.34 ng/mL (n = 26; sulfonylureas-combination n = 13 and
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et al., 2013). This may be due to 1) our longer observational period, 2)
the higher bodyweight with HbA1c b 7.0% at 54 weeks and/or 3) the
speciﬁcity of the present cut-off point to predict long-term efﬁcacy of
liraglutide without any additional OADs. Since liraglutide has recently
received new indications for co-administration with several OADs
other than SU or insulin in Japan, β-cell function cut-off values for the
efﬁcacy of these combinations need to be determined.
Whether or not these cut-off values predict efﬁcacy of other GLP-1
receptor agonists is not known. Recently, short- and long-acting GLP-1
receptor agonists have been shown to exert their glucose-lowering effects
differently (Meier, 2012; Yabe & Seino, 2014). Long-acting agents
ameliorate defects in islet function; short-acting agents inhibit gastric
emptying. Consistently, the HbA1c-lowering effects of long-acting liraglu-
tide but not those of the short-acting exenatide and lixisenatide dependon
remaining β-cell function for their efﬁcacy (Meier et al., 2011; Meier et al.,
2013). It will be interesting to investigate association of remaining β-cell
function with HbA1c-lowering effects of ultra-long-acting GLP-1 receptor
agonists such as exenatide long-acting release, albiglutide, and duraglutide
as well as those of dipeptidyl peptidase-4 inhibitors.
In the current study, liraglutide monotherapy and SU-combination
therapy were analyzed in the same group due to limited sample size.
Subjects who started liraglutide asmonotherapy had longer duration inwhich to receive additional OADs including SU (Table 1); subjects who
started liraglutide as SU-combination tended to have higher HbA1c at
54 weeks among those receiving no additional OAD for 54 weeks (data
not shown). The percentage of SU-combination therapy was lower in
patients receiving additional OAD (Table 1), suggesting that some
patients received SU-combination therapy even though physicians in
charge selectedmonotherapy. Future studies are required to analyze the
association of remaining β-cell function with liraglutide monotherapy
and SU-combinations separately, along with analysis in relation to
liraglutide combinations with other OADs and insulin.
Remaining β-cell function did not affect weight reduction (Fig. 2).
Liraglutide has been shown to suppress food intake and reduce
bodyweight in mice lacking the GLP-1 receptor speciﬁcally in the
peripheral nervous system but not in the central nervous system
(Sisley et al., 2014). FunctionalMRI in individuals with type 2 diabetes
revealed that the GLP-1 receptor agonist exenatide activates
appetite- and reward-related brain areas (van Bloemendaal et al.,
2014). Subcutaneously injected liraglutide in rats migrates and
binds to GLP-1 receptors expressed in the arcuate nuclei of the
hypothalamus, the brain region responsible for appetite control
(Secher et al., 2014). These ﬁndings suggest direct actions of GLP-1
receptor agonist that reduce appetite and bodyweight indepen-
dently of β-cell function.
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1209R. Usui et al. / Journal of Diabetes and Its Complications 29 (2015) 1203–1210The current study has limitations other than those described above,
and caution is required. First, due to the nature of retrospective studies,
there were no protocols for initiating liraglutide as monotherapy or
SU-combination therapy, addingOADs or switching to insulin injections
or reporting adverse events including hypoglycemia. Second, the
number of subjects examined in this retrospective study is small.
Furthermore, our analysiswas conductedamong subjectswithGSTdata,
who tend to have higher baseline HbA1c and to receive liraglutide
initiation during their hospitalization. However, demographics other
than baseline HbA1c were similar between subjects with and without
GSTdata, suggesting that our ﬁndingsmight be generalized. Third, there
were no inclusion or exclusion criteria for GST or liraglutide initiation
due to the nature of retrospective studies. Although anti-diabetic drugs
such as SU and insulin are known to affect the response to glucagon
stimulation tests (Albareda et al., 2005), anti-diabetic drugs including
insulin were not terminated until the night before GST, since
hyperglycemia itself is known to affect GST (Nosari, Lepore, Maglio,
Cortinovis, & Pagani, 1992). Fourth, higher bodyweight at 0 week
suggests greater insulin resistance in patients achieving HbA1c b7.0% at
54 weeks, which might affect our cut-off value. Analysis with a larger
sample size is required for adjustment for bodyweight and degree of
insulin resistance in evaluation of the requirement for remaining β-cell
function in regard to long-term glycemic control by liraglutide.
In conclusion, remaining β-cell function, assessed by GST-ΔCPR,
plays a pivotal role in predicting long-term glycemic control by
liraglutide. While further studies are needed for insulin- or other
OAD-combination therapies, the cut-off value GST-ΔCPR 2.34 may be
informative for classiﬁcation of patients before initiation of liraglutide
as monotherapy or SU-combination therapy.Acknowledgement
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